Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.

Optimization of a lead thiazole amide MF-152 led to the identification of potent bicyclic heteroaryl SCD1 inhibitors with good mouse pharmacokinetic profiles. In a view to target the liver for efficacy and to avoid SCD1 inhibition in the skin and eyes where adverse effects were previously observed in rodents, representative systemically-distributed SCD1 inhibitors were converted into liver-targeting SCD1 inhibitors.

[1]  B. Monia,et al.  Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. , 2006, The Journal of clinical investigation.

[2]  Margaret S. Wu,et al.  Prevention of obesity in mice by antisense oligonucleotide inhibitors of stearoyl-CoA desaturase-1. , 2005, The Journal of clinical investigation.

[3]  M. Miyazaki,et al.  The Biosynthesis of Hepatic Cholesterol Esters and Triglycerides Is Impaired in Mice with a Disruption of the Gene for Stearoyl-CoA Desaturase 1* , 2000, The Journal of Biological Chemistry.

[4]  R. Oballa,et al.  Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[5]  B. Yandell,et al.  Loss of stearoyl–CoA desaturase-1 function protects mice against adiposity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Manabu T. Nakamura,et al.  STRUCTURE, FUNCTION, AND DIETARY REGULATION OF Δ6, Δ5, AND Δ9 DESATURASES , 2004 .

[7]  David A. Powell,et al.  Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia. , 2011, Journal of medicinal chemistry.

[8]  J. Guay,et al.  Thiazole analog as stearoyl-CoA desaturase 1 inhibitor. , 2009, Bioorganic & medicinal chemistry letters.

[9]  M. Yamada,et al.  Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine]. , 2010, Bioorganic & medicinal chemistry letters.

[10]  A. I. Glushkov,et al.  Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[11]  J. Falgueyret,et al.  Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438). , 2010, Bioorganic & medicinal chemistry letters.

[12]  H. Enoch,et al.  Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. , 1976, The Journal of biological chemistry.

[13]  J. Ntambi,et al.  The regulation of stearoyl-CoA desaturase (SCD). , 1995, Progress in lipid research.

[14]  R. Oballa,et al.  SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[15]  C. Steppan,et al.  N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[16]  A. Brownlie,et al.  Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200189-JLR200 , 2002, Journal of Lipid Research.

[17]  J. Falgueyret,et al.  2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[18]  A. Dobrzyń,et al.  Stearoyl‐CoA desaturase as a new drug target for obesity treatment , 2005, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[19]  H. Sham,et al.  Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[20]  J. Guay,et al.  A Multiplexed Cell Assay in HepG2 Cells for the Identification of Delta-5, Delta-6, and Delta-9 Desaturase and Elongase Inhibitors , 2010, Journal of biomolecular screening.

[21]  E. Hoffman,et al.  Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. , 2005, Cell metabolism.

[22]  A. Dobrzyń,et al.  The role of stearoyl-CoA desaturase in the control of metabolism. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[23]  Mikko Niemi,et al.  Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.